ArriVent BioPharma, Inc. (AVBP) vs Inhibrx Biosciences Inc. (INBX)
A side-by-side comparison of ArriVent BioPharma, Inc. and Inhibrx Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$12.88HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
INBX
Inhibrx Biosciences Inc.
$96.74HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — AVBP vs INBX
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)INBX +164.6% (+38.3%/yr)INBX compounded faster over this window
AVBP INBX
AVBP vs INBX: by the numbers
- •INBX is the larger company ($1.42B vs $600M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | AVBP | INBX |
|---|---|---|
| P/B ratio | 1.64 | N/A |
Profitability
| Metric | AVBP | INBX |
|---|---|---|
| Gross margin | 0.00% | -91.00% |
| Operating margin | 0.00% | -10386.54% |
| Net margin | 0.00% | -10773.46% |
| ROE | -44.63% | N/A |
| ROIC | -47.96% | -99.35% |
Growth (annualized)
| Metric | AVBP | INBX |
|---|---|---|
| Total return CAGR (5Y) | N/A | 27.64% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.